D2 Versus D4 Corifollitropin Alfa in GnRH Antagonists

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the present study is to analyse if corifollitropin alfa, an agent for prolonged ovarian stimulation, administered from day 4 can be clinically used instead of day 2 onwards for a controlled ovarian hyperstimulation (COH) in an antagonist protocol.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitair Ziekenhuis Brussel

Criteria

Inclusion Criteria:

• < 36 years old on day of randomisation

• FSH < 12 (in the early follicular phase)

• Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality within 6 months prior to randomisation.

• Regular menstrual cycles of 21-35 days, presumed to be ovulatory.

• BMI ≤ 29

• Weight > 60 kg

• < 3 previous trials

• ICSI

• Randomisation at out-patient clinic

Exclusion Criteria:

• ≥ 36 years old on day of randomisation

• Endometriosis ≥ grade 3

• PCOS

• Poor responders (development of < 4 follicles in a previous IVF/ICSI cycle)

• Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)